Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
56 participants
INTERVENTIONAL
2010-02-28
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tocilizumab
Infusion of Tocilizumab and sport intervention
Sport
Tocilizumab
Sitagliptin
Intake of Sitagliptin and sport intervention
Sport
Sitagliptin
Placebo
Intake of placebo and sport intervention
Sport
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sport
Tocilizumab
Sitagliptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetes group: Type 2 diabetes according to American Diabetes Association criteria
Exclusion Criteria
* Diabetes duration of more than 5 years
* Inflammatory diseases
* Current infection
* Liver disease (transaminases \>2x upper normal range)
* kidney disease (creatinine \>1.5 mg/dl for men and 1.4 mg/dl for women)
* pregnancy or breast-feeding, women of child bearing potential not using an acceptable form of contraception
* immunosuppressive disease
* corticosteroid use
* regular non-steroidal antinflammatory drug usage
* history of carcinoma
* history of tuberculosis
* anemia, bleeding disorders
* obstructive pulmonary disease.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Foundation for the Study of Diabetes
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
01 Studienregister MasterAdmins
Role: STUDY_DIRECTOR
UniversitaetsSpital Zuerich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ellingsgaard H, Seelig E, Timper K, Coslovsky M, Soederlund L, Lyngbaek MP, Wewer Albrechtsen NJ, Schmidt-Trucksass A, Hanssen H, Frey WO, Karstoft K, Pedersen BK, Boni-Schnetzler M, Donath MY. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study. Diabetologia. 2020 Feb;63(2):362-373. doi: 10.1007/s00125-019-05045-y. Epub 2019 Dec 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Donath-1
Identifier Type: -
Identifier Source: org_study_id